Federal Register Notices

View Federal Register notices of proposed exclusive licenses. Clicking on the "View" links will display the Federal Register Notice in a new tab. You can also search directly on the Federal Register site.

View Date Published Title Comments Close On Dates
View National Institutes of Health Clinical Center: Cooperative Research and Development Agreement (CRADA) Opportunity for the Development of Medical Magnetic Imaging Methods for Diagnostic or Therapeutic Purposes Interested parties should submit a one page statement of interest that outlines the proposed research project and addresses the collaborator's ability to fulfill its collaborative responsibilities. The statement of interest should be submitted in writing no later than August 14, 2000. CRADA proposals submitted thereafter may be considered if a suitable CRADA collaborator has not been found.
View Prospective Grant of Exclusive License: Pressure Mediated Selective Delivery of Therapeutic Substances and Cannula Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before September 11, 2000, will be considered.
View Prospective Grant of Exclusive License: “Highly Elastic, Adjustable Helical Coil Stent” Only written comments and or license applications which are received by the National Institutes of Health on or before October 10, 2000 will be considered.
View Prospective Grant of Exclusive License: Antagonists of the αEβ7 Integrin as Therapeutic Agents for Inflammatory Diseases Only written comments and/or license applications which are received by the National Institutes of Health on or before August 11, 2000 will be considered.
View Prospective Grant of Co-exclusive License: “Ultra Thin Walled Wire Reinforced Endotracheal Tubing” Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before August 7, 2000 will be considered.
View Prospective Grant of Exclusive License: “Anti-Notch Antibodies and Pharmaceutical Compositions for the Therapeutic Treatment of Tumors Which Over Express Notch Protein” Only written comments and/or applications for a license which are received by NIH on or before July 31, 2000 will be considered.
View Prospective Grant of Exclusive License: “Antitumor Macrocyclic Lactones, Compositions and Methods of Use” and “Vacuolar-Type (H+)-ATPase-Inhibiting Compounds, Compositions, and Uses Thereof” Only written comments and/or license applications which are received by the National Institutes of Health on or before July 31, 2000 will be considered.
View Prospective Grant of Exclusive License: Recombinant Virus Expressing Human Carcinoembryonic Antigen and Methods of Use Thereof Only written comments and/or license applications which are received by the National Institutes of Health on or before July 31, 2000 will be considered.
View Prospective Grant of Exclusive License: Uridine Prodrug Analogues: Uses in Cancer Diagnosis and Therapy Only written comments and/or license applications which are received by the National Institutes of Health on or before July 17, 2000 will be considered.
View Prospective Grant of Exclusive License: NMR Glomerular Filtration Test and Kit Only written comments and/or applications for a license which are received by NIH on or before June 23, 2000 will be considered.
View Prospective Grant of Exclusive License: Second Generation Monoclonal Antibodies, and Humanized Carcinomas Only written comments and/or license applications which are received by the National Institutes of Health on or before June 23, 2000 will be considered.
View Prospect Grant of Exclusive License: Therapeutic and Diagnostic Uses of Novel Thiolesters for HIV and Other Applications Only written comments and/or license applications which are received by the NIH Office of Technology Transfer on or before June 19, 2000 will be considered.
View National Cancer Institute (NCI) and the NIH Center for Information Technology (CIT): Opportunity for a Cooperative Research and Development Agreement (CRADA) for the Development of Software Enhancement for Expanding the Medical Uses of the TELESYNERGYTM Medical Consultation Workstation Interested parties should notify the Technology Development and Commercialization Branch of the NCI in writing of their interest in filing a formal proposal no later than thirty (30) days from the date of this announcement. Potential CRADA Collaborators will then have an additional thirty (30) days to submit a formal proposal. CRADA proposals submitted thereafter may be considered if a suitable CRADA Collaborator has not been selected.
View Prospective Grant of Exclusive License: Development of Instruments for Diagnostic and Surgical Applications Based on Spectroscopic and Hyperspectral Imaging Techniques Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before July 3, 2000 will be considered.
View National Cancer Institute: Opportunity for a Cooperative Research and Development Agreement (CRADA) for the Screening, Development and Commercialization of Novel Inhibitors of GADD45 Polypeptide Activity for the Treatment of Cancer Interested parties should notify the Technology Development and Commercialization Branch of the NCI in writing of their interest in filing a formal proposal no later than May 26, 2000. Potential CRADA Collaborators will then have an additional thirty (30) days to submit a formal proposal. CRADA proposals submitted thereafter may be considered if a suitable CRADA Collaborator has not been selected.
View National Cancer Institute: Opportunity for a Cooperative Research and Development Agreement (CRADA) for the Research, Purification, and Further Development of a Factor(s) That Inhibits Human Immunodeficiency Virus (HIV) Replication Interested parties should notify this office in writing of their interest in filing a formal proposal no later than May 26, 2000. Potential CRADA Collaborators will then have an additional thirty (30) days to submit a formal proposal. CRADA proposals submitted thereafter may be considered if a suitable CRADA Collaborator has not been selected.
View National Cancer Institute; Steroid Derivatives with Paclitaxel-Like Activity Inquiries regarding CRADA proposals and scientific matters may be forwarded at any time. Confidential preliminary CRADA proposals, preferably two pages or less, must be submitted to the NCI on or before June 20, 2000. Guidelines for preparing final CRADA proposals will be communicated shortly thereafter to all respondents with whom initial confidential discussions will have established sufficient mutual interest.
View National Cancer Institute; Targeted Screening for Inhibitors of Human Herpesvirus 8 DNA Polymerase Activity Inquiries regarding CRADA proposals and scientific matters may be forwarded at any time. Confidential, preliminary CRADA proposals, preferably two pages or less, must be submitted to the NCI within 30 days from date of this publication. Guidelines for preparing final CRADA proposals will be communicated shortly thereafter to all respondents with whom initial confidential discussions will have established sufficient mutual interest.
View Prospective Grant of Exclusive License: Use of Thymosin β4 for Wound Healing Applications Only written comments and/or license applications which are received by the National Institutes of Health on or before May 30, 2000 will be considered.
View Prospective Grant of Exclusive License: Uteroglobin in Treatment of IgA Mediated Autoimmune Disorders Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before May 18, 2000.
View Prospective Grant of Exclusive License: “Antibodies to Human Cripto Protein” and “Antibodies Specific for Human Cripto-Related Polypeptide CR-3” Only written comments and/or license applications which are received by the National Institutes of Health on or before April 17, 2000 will be considered.
View Prospective Grant of Exclusive License: Autotaxin: Motility Stimulating Protein Useful in Cancer Diagnosis and Therapy Only written comments and/or license applications which are received by the National Institutes of Health on or before April 17, 2000 will be considered.
View National Cancer Institute: Development of Idiotype Tumor Vaccines for Treatment of B-Cell Lymphoma Organizations must submit a proposal summary preferably one page or less, to NCI within 90 days from date of this publication. Guidelines for preparing full CRADA proposals will be communicated shortly thereafter to all respondents with whom initial discussions will have established sufficient mutual interest.
View Prospective Grant of Exclusive License: Nitroxides as Protectors Against Oxidative Stress and the Prophylactic and Therapeutic Treatment Radiation Damage to Normal Tissue Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before May 8, 2000, will be considered.
View Prospective Grant of Exclusive License: Nitroxides as Protectors Against Oxidative Stress and in the Prophylactic and Therapeutic Treatment of Aging, Obesity and Cancer Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before May 8, 2000, will be considered.